Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts
McKinsey
Dow
Mallinckrodt

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR ROSIGLITAZONE MALEATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Rosiglitazone Maleate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004180 ↗ Rosiglitazone in Treating Patients With Liposarcoma Completed National Cancer Institute (NCI) Phase 2 1999-10-01 RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma.
NCT00004180 ↗ Rosiglitazone in Treating Patients With Liposarcoma Completed Dana-Farber Cancer Institute Phase 2 1999-10-01 RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma.
NCT00015691 ↗ Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 The purpose of this study is to see whether metformin alone, rosiglitazone alone, or metformin and rosiglitazone together will lower insulin levels in the blood and decrease fat in the abdomen or other parts of the body. Studies have shown that certain anti-HIV medications can cause a number of side effects, including high blood sugar (resulting from the body's failure to use insulin), high insulin, and excess fat build-up in the abdominal area. These side effects are known to increase the risk of heart disease. Metformin and rosiglitazone are 2 drugs that have been shown to lower insulin resistance and lessen abdominal fat in patients who are not HIV-infected. This study will investigate the use of these drugs in HIV-infected patients.
NCT00084578 ↗ Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder Withdrawn National Cancer Institute (NCI) N/A 2004-03-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Rosiglitazone may help tumor cells develop into normal bladder cells. PURPOSE: This randomized clinical trial is studying how well giving celecoxib together with rosiglitazone works in treating patients who are undergoing cystoscopic surveillance (screening) for early-stage noninvasive (carcinoma in situ) carcinoma (cancer) of the bladder or radical cystectomy for muscle-invasive carcinoma (cancer has spread into the muscle layer of bladder tissue) of the bladder.
NCT00084578 ↗ Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder Withdrawn Fox Chase Cancer Center N/A 2004-03-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Rosiglitazone may help tumor cells develop into normal bladder cells. PURPOSE: This randomized clinical trial is studying how well giving celecoxib together with rosiglitazone works in treating patients who are undergoing cystoscopic surveillance (screening) for early-stage noninvasive (carcinoma in situ) carcinoma (cancer) of the bladder or radical cystectomy for muscle-invasive carcinoma (cancer has spread into the muscle layer of bladder tissue) of the bladder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rosiglitazone Maleate

Condition Name

Condition Name for Rosiglitazone Maleate
Intervention Trials
Diabetes Mellitus, Type 2 5
HIV Infections 3
Diabetes Mellitus 2
Atherosclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rosiglitazone Maleate
Intervention Trials
Diabetes Mellitus 10
Diabetes Mellitus, Type 2 9
HIV Infections 3
Atherosclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rosiglitazone Maleate

Trials by Country

Trials by Country for Rosiglitazone Maleate
Location Trials
United States 129
Germany 16
Mexico 12
Canada 8
Italy 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rosiglitazone Maleate
Location Trials
California 9
New York 6
Maryland 5
Indiana 5
Massachusetts 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rosiglitazone Maleate

Clinical Trial Phase

Clinical Trial Phase for Rosiglitazone Maleate
Clinical Trial Phase Trials
Phase 3 9
Phase 2 5
Phase 1 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rosiglitazone Maleate
Clinical Trial Phase Trials
Completed 17
Terminated 2
Withdrawn 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rosiglitazone Maleate

Sponsor Name

Sponsor Name for Rosiglitazone Maleate
Sponsor Trials
GlaxoSmithKline 9
National Cancer Institute (NCI) 6
National Institutes of Health (NIH) 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rosiglitazone Maleate
Sponsor Trials
Industry 17
NIH 9
Other 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Moodys
Mallinckrodt
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.